Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Context Therapeutics Q1 EPS $(0.05) Beats $(0.09) Estimate

Author: Benzinga Newsdesk | May 07, 2025 05:27pm
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.09) by 44.44 percent. This is a 78.26 percent increase over losses of $(0.23) per share from the same period last year.

Posted In: CNTX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist